GARDASIL Drug Profile

Summary for Tradename: GARDASIL

High Confidence Patents:	10
Applicants:	1
BLAs:	2
Recent Clinical Trials:	See clinical trials for GARDASIL

Recent Clinical Trials for GARDASIL

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
MGB Pharma	PHASE1
PharmaJet, Inc.	Phase 2
National Institutes of Health (NIH)	Phase 2

See all GARDASIL clinical trials

Pharmacology for GARDASIL

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Human Papillomavirus Vaccine
Chemical Structure	Papillomavirus Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GARDASIL Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GARDASIL Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	GARDASIL	human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant	Injection	125126	10,016,338	2036-12-20	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL	human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant	Injection	125126	10,286,058	2035-01-13	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL	human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant	Injection	125126	10,556,894	2035-11-09	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL	human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant	Injection	125126	10,561,723	2036-07-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for GARDASIL Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	GARDASIL	human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant	Injection	125126	10,016,338	2036-12-20	Patent claims search
Merck Sharp & Dohme Llc	GARDASIL	human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant	Injection	125126	10,286,058	2035-01-13	Patent claims search
Merck Sharp & Dohme Llc	GARDASIL	human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant	Injection	125126	10,556,894	2035-11-09	Patent claims search
Merck Sharp & Dohme Llc	GARDASIL	human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant	Injection	125126	10,561,723	2036-07-21	Patent claims search

International Patents for GARDASIL

Country	Patent Number	Estimated Expiration
South Africa	201107871
Portugal	1673106
Austria	E234925
Germany	122007000086

Supplementary Protection Certificates for GARDASIL

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2015 00066	Denmark		PRODUCT NAME: HPV 45 L1 PROTEIN INCLUDING HPV 45 L1 VLPS; REG. NO/DATE: EU/1/15/1007 20150612
132007901501582	Italy		AUTHORISATION NUMBER(S) AND DATE(S): GARDASIL: EU/1/06/357/001-017; SILGARD: EU/1/06/358/001-017, 20060920
CA 2007 00066	Denmark
122015000106	Germany		PRODUCT NAME: L1-PROTEIN VOM TYP 45 DES HUMANEN PAPILLOMAVIRUS, IN DER DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORM; REGISTRATION NO/DATE: EU/1/15/1007/001-003 20150610

Market Dynamics and Financial Trajectory for GARDASIL

Last updated: February 19, 2026

GARDASIL, a prophylactic vaccine developed by Merck & Co. for prevention of human papillomavirus (HPV) infections, dominates the HPV vaccine market. It addresses cervical and other HPV-related cancers and genital warts, with strong global sales and expanding demand in emerging markets. This report details current market landscape, growth drivers, competitive positioning, and financial projections.

Market Overview and Current Position

GARDASIL was approved by the FDA in 2006. Merck currently holds a dominant position, accounting for approximately 80% of global HPV vaccine sales in 2022. The vaccine’s sales revenue hit $3.2 billion in 2022, a slight decline from the peak of $3.4 billion in 2021, correlating with broader COVID-19 disruptions.

The HPV vaccine market includes two major competitors: Merck’s GARDASIL and GlaxoSmithKline’s (GSK) Cervarix. GARDASIL 9 is the most widely used formulation, covering nine HPV types, including the high-risk HPV 16 and 18. The GARDASIL franchise is also characterized by its broad age-range approval, from 9 years to 45 in many jurisdictions.

Market Drivers

Expanding Immunization Programs: Governments worldwide adopt expanded vaccination policies. For example, the U.S. CDC recommends routine vaccination for boys and girls aged 11-12, with catch-up vaccination for up to age 26[1].

Growing Global Awareness: Awareness campaigns and cervical cancer screening drive public acceptance. The World Health Organization (WHO) targets 90% of girls vaccinated by 15 years old by 2030.

Emerging Markets Expansion: Increasing vaccine access in Latin America, Southeast Asia, and Africa propels sales. Prices are lower but volume growth compensates.

Vaccine Schedule Updates: Inclusion of HPV vaccination in national immunization programs increases doses administered annually.

Challenges and Market Risks

Vaccine Hesitancy: Misinformation and cultural barriers affect uptake in several countries.

Pricing Pressure: Competition from biosimilars and domestic manufacturing efforts challenge GARDASIL’s premium pricing.

Regulatory Dynamics: Approval for broader populations or new formulations (e.g., therapeutic vaccines) remains uncertain, affecting long-term outlooks.

Patent Expiry: GARDASIL’s primary patents expire around 2027, opening markets for biosimilar competition, potentially reducing prices.

Financial Trajectory and Projections

Year	Revenue (USD billion)	Growth Rate	Comments
2022	3.2	-5.9%	Slight decline amid COVID-19 disruptions
2023	3.4	6.25%	Rebound driven by increased vaccination programs
2024	3.5	2.9%	Market stabilization
2025	3.6	2.9%	Steady demand, new markets introduction
2026	3.8	5.6%	Pre-patent expiry prices maintained
2027	3.5	-7.9%	Patent expiry, biosimilar entry begins

Assumption: Growth driven by volume increases, offset by pricing pressures post-patent.

Competitive Dynamics and Patent Outlook

GARDASIL’s patent protection in the U.S. extends until 2027. Biosimilar competition is expected to emerge shortly after, particularly in Europe and emerging markets where patent enforcement is less strict. Merck invests in third-generation vaccines (e.g., nonavalent formulations with broader coverage) to maintain a competitive edge.

Pricing and Reimbursement Policies

In developed markets, GARDASIL’s price typically ranges from $150–$250 per dose, with a three-dose schedule. Reimbursement depends on national healthcare policies, with vaccination often included in public health programs, reducing out-of-pocket expenses. In low-income countries, GARDASIL’s cost is negotiated down to support access.

R&D and Pipeline Outlook

Merck continues to invest in expanding HPV vaccination indications, including therapeutic vaccines. Development of vaccines targeting additional HPV types or other oncogenic viruses remains ongoing. The pipeline is modest, focusing mainly on improved formulations and new delivery methods.

Key Market Opportunities

• Rollout of HPV vaccination programs in Africa and Southeast Asia
• Development of therapeutic HPV vaccines
• Expansion of age indications in adult populations
• Diversification into combination vaccines

Key Challenges

• Overcoming vaccine hesitancy in certain demographics
• Navigating patent expirations and biosimilar entry
• Maintaining market share amid pricing pressures
• Addressing logistical barriers in low-resource settings

Strategic Recommendations

• Accelerate access programs in emerging markets
• Invest in public awareness campaigns
• Develop next-generation vaccines with broader protection
• Strengthen patent filings and intellectual property strategies

Key Takeaways

• GARDASIL remains a leading HPV vaccine with approximately $3.2 billion in global sales in 2022.
• Market growth is influenced by government immunization policies, global awareness, and emerging markets.
• Patent expiration in 2027 will introduce biosimilar competition, pressuring revenues.
• Growth beyond patent expiry depends on introduction of next-generation formulations and expansion into therapeutic indications.
• Pricing strategies and reimbursement policies significantly impact market penetration and revenue.

FAQs

1. When will GARDASIL patents expire, and what is the impact?
Patents in the U.S. expire in 2027, enabling biosimilar competitors, which can reduce Merck’s market share and pricing power.

2. How does GARDASIL compare to its main competitor, Cervarix?
GARDASIL 9 covers nine HPV types including types 6 and 11 (warts), while Cervarix covers only HPV types 16 and 18. GARDASIL’s broader coverage results in higher sales.

3. What are the major markets for GARDASIL beyond the U.S.?
Europe, Asia-Pacific, Latin America, and Africa are key growth areas due to expanding immunization programs and national health initiatives.

4. How are vaccination rates trending globally?
Rates are increasing in high-income countries but remain low in some low-income nations due to access, cost, and cultural barriers.

5. What is the outlook for therapeutic HPV vaccines?
Therapeutic candidates are in early development phases. Success could open new revenue streams but remain uncertain due to clinical and regulatory challenges.

---

References

[1] Centers for Disease Control and Prevention. (2022). HPV vaccine recommendations. CDC.gov.